Eli Lilly and Company $LLY Stock: USS Investment Management Ltd Lowers Holdings

USS Investment Management Ltd lessened its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 137,631 shares of the company’s stock after selling 2,056 shares during the quarter. Eli Lilly and Company makes up about 0.6% of USS Investment Management Ltd’s holdings, making the stock its 24th largest position. USS Investment Management Ltd’s holdings in Eli Lilly and Company were worth $159,612,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. State Street Corp raised its position in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in Eli Lilly and Company by 7.9% during the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after purchasing an additional 400,538 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on LLY shares. Bank of America reaffirmed a “buy” rating and issued a $1,497.00 price target on shares of Eli Lilly and Company in a report on Friday, October 30th. Sanford C. Bernstein reissued an “outperform” rating and set a $1,450.00 price objective on shares of Eli Lilly and Company in a report on Monday, October 26th. UBS Group boosted their price objective on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. TD Cowen restated a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,422.00.

Read Our Latest Report on LLY

Key Stories Impacting Eli Lilly and Company

These are some of the LLY stories that stood out recently:

  • Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce major cardiovascular risks in adults with type 2 diabetes and established cardiovascular disease, expanding the medicine’s potential use. Health Canada approves Lilly’s Mounjaro to reduce cardiovascular risk
  • Neutral Sentiment: Lilly’s 2026 acquisition spending has surpassed $32 billion, including deals aimed at building cancer and immunology capabilities. The investments could strengthen future growth but also raise execution and capital-allocation questions. Lilly buying spree surpasses $32 billion
  • Negative Sentiment: A report that Lilly stopped highlighting dose counts prompted questions about what the change signals for demand and disclosure, adding uncertainty around its obesity-drug growth story. Separately, State Street’s health-care ETF sold $42.3 million of Lilly shares, a potential source of near-term selling pressure. Eli Lilly stopped touting dose counts. Should you worry?

Eli Lilly and Company Stock Down 2.2%

Eli Lilly and Company stock opened at $1,352.18 on Friday. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a market capitalization of $1.27 trillion, a P/E ratio of 43.89, a PEG ratio of 1.65 and a beta of 0.40. The stock has a 50-day simple moving average of $1,263.45 and a 200-day simple moving average of $1,117.53.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business’s revenue was up 38.6% on a year-over-year basis. During the same period in the prior year, the firm earned $7.02 EPS. Equities research analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.